Toward molecular strategies for heart disease: Past, present, future

Japanese Circulation Journal

Volumn 61, Issue 2, 1997, Pages 91-118

  Chien, Kenneth R ^a,b,c   Shimizu, Mitsuyuki ^a,d   Hoshijima, Masahiko ^a   Minamisawa, Susumu ^a   Grace, Andrew A ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cardiology; Genetic; Heart disease

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBOCYTIC AGENT; COMPLEMENTARY DNA; DISINTEGRIN; EPTIFIBATIDE; FIBRIN ANTIBODY; FIBRINOGEN RECEPTOR ANTAGONIST; FIBROBLAST GROWTH FACTOR; GENE PRODUCT; GROWTH FACTOR; HIRUDIN; KISTRIN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; RO 43 5054; RO 4483; SYNTHETIC PEPTIDE; THROMBOCYTE ANTIBODY; THROMBOPOIETIN; THROMBOSPONDIN; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; ATHEROSCLEROSIS; BIOTECHNOLOGY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG MANUFACTURE; GENE THERAPY; GENETIC ENGINEERING; HEART DISEASE; HEART VENTRICLE HYPERTROPHY; HUMAN; MOLECULAR GENETICS; MOLECULAR MODEL; NONHUMAN; PHENOTYPE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; FORECASTING; GENE THERAPY; HEART DISEASES; HUMANS; MICE;

EID: 0030892443     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.61.91     Document Type: Article

References (206)

1. Chien KR: Molecular advances in cardiovasculr Biology. Science 1993; 260: 916-917
2. Lewin B: Genes V. (5th edition) Oxford: Oxford University Press, 1994
3. Watson JD, Gilman M, Witkowski J, Zoller M: Recombinant DNA. (2nd edition) New York: Scientific American Books, 1992
4. Rosenthal N: General principles of molecular biology. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: W. B. Saunders Company, 1997
5. Chien KR, editor. Molecular basis of heart disease (in preparation). (1st edition) Philadelphia: W. B. Saunders Company, 1998
6. Ward WHJ, Timms D, Fersht AR: Protein engineering and the study of structure-function relationships in receptors. Trends Pharmacol Sci 1990; 11: 280-284
7. Erslev A: Erythropoietin. N Engl J Med 1991; 324: 1339-1344
8. Schick BP: Hope for treatment of thrombocytopenia. N Engl J Med 1994; 331: 875-876
9. Gerard RD., Chien KR, Meidell RS: Molecular biology of tissue plasminogen activator and endogenous inhibitors. Mol Biol Med 1986; 3: 449-457
10. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124
11. Deutsch E, Rao AK, Colman RW: Selective thrombin . inhibitors: the next generation of anticoagulants. J Am Coll Cardiol 1993; 22: 1089-1092
12. Lefkovits J, Topol EJ: Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-1536
13. Coughlin SR: Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med 1994; 4: 77-83
14. Badimon L, Merino A, Badimon J, Chesebro JH, Fuster V: Hirudin and other thrombin inhibitors. Experimental results and potential clinical applications. Trends Cardiovasc Med 1991; 1: 261-267
15. Ferrara N: Vascular endothelial growth factor. Trends Cardiovasc Med 1993; 3: 244-250
16. Winter G, Milstein C: Man-made antibodies. Nature 1991; 349: 293-299
17. Ritter MA, and Ladyman HM, editors. Monoclonal antibodies. Production, Engineering and Clinical application. Cambridge: Cambridge University Press, 1995
18. Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 1988; 332: 323-327
19. Brugge JS: New intracellular targets for therapeutic drug design. Science 1993; 260: 918-919
20. Goody RS: Rational drug design and HIV: hopes and limitations. Nature Med 1995; 1: 519-520
21. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559
22. Shattil S, Ruggieri Z: Platelets. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: WB Saunders Co, 1997
23. Jang Y, Lincoff AM, Plow EF, Topol EJ: Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-1601
24. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E: Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559-1562
25. Hynes RO: Integrins: A family of cell surface receptors. Cell 1987; 48: 549 -554
26. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25
27. Phillips DR, Charo IF, Scarborough RM: GPIIb-IIIa: the responsive integrin. Cell 1991; 65: 359 -362
28. Calvete JJ: Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoprotein IIb/IIIa complex. Thromb Hemostas 1994; 72: 1-15
29. Baldwin HS, Buck CA: Integrins and other cell adhesion molecules in cardiac development. Trends Cardiovasc Med 1994; 4: 178-187
30. Pierschbacher MD, Ruoslahti E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-33
31. 3 (platelet GPIIb-IIIa). Cell 1991; 65: 409-416
32. Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, et al: Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of j platelet aggregation inhibitors. Proc Natl Acad Sci 1990; 87: 2471-2475
33. Shebuski RJ, Ramjit DR., Bencen GH, Polokoff MA: Characterisation and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans. J Biol Chem 1989; 264: 21550-21556
34. Bangs NU, Clayman MD: Antithrombotic agents from salivary glands of hematophagous animals. Trends Cardiovasc Med 1992; 2: 183-188
35. Scarborough RM, Naughton MA, Teng W, Rose JW, Philipps DR, Nannizzi L, et al: Design of potent and specific integrin antagonists. J Biol Chem 1993; 268: 1066-1073
36. Adler M, Lazarus RA, Dennis MS, Wagner G: Solution structure of kistrin, a potent platelet aggregation inhibitor and GPIIb-IIIa antagonist. Science 1991; 253: 445-448
37. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ: Multicenter, randomized, double-blind, placebo-controlled trial of platelet integrin glycoprotein IIb/IIIa blocker intergrelin in elective coronary intervention. Circulation 1995; 91: 2151-2157
38. Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B: Reversible informational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 1992; 80: 2539-2547
39. The EPIC investigators: Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
40. Harker LA: Platelets and vascular thrombosis. N Engl J Localization of Cardiovascular Disease Genes
41. Beaudet AL, Scriver CR, Sly WS, Valle D: Genetics, biochemistry, and molecular basis of variant human phenotypes. In: Scriver C, Beaudet A, Sly W, Vale D, editors. The metabolic and molecular bases of inherited disease. (7th edition) New York: McGraw-Hill, 1995; 53. vol 3
42. White R, Caskey CT: The human as an experimental system in molecular genetics. Science 1988; 240: 1483-1488
43. Collins FS: Positional cloning moves from perditional to traditional. Nature Genetics 1995; 9: 347-350
44. Fields C, Adams MD, White O, Venter JC: How many genes in the human genome? Nature Genet 1994; 7: 345-346
45. Goodfellow PN: Microsatellites and the new genetic maps. Curr Biol 1993; 3: 149-151
46. Botstein D, White RL, Skolnick M, Davis RW: Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Gen 1980; 32: 314-331
47. Housman D: Human DNA polymorphism. N Engl J Med 1995; 332: 318-320
48. Green ED, Cox DR, Myers RM: The human genome project and its impact on the study of human disease. In: Scriver CR, Beaudet AL, Sly WS, Vale D, editors. The metabolic and molecular bases of inherited disease. (7th edition) New York: McGraw-Hill, 1995: 401. vol 3.
49. Aldhous P: Fast track to disease genes. Science 1994; 265: 2008-2010
50. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS: Diagnostic criteria for the long QT syndrome. An update. Circulation 1993; 88: 782-784
51. Schwartz PJ, Locati EH, Napolitano C, Priori SG: The long QT syndrome. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: from cell to bedside. Philadelphia: WB Saunders Co, 1995: 788
52. Moss AJ, Robinson JL: The long-QT syndrome. Genetic considerations. Trends Cardiovasc Med 1992; 2: 81-83
53. Vincent GM, Timothy KW, Leppert M, Keating MT: The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327: 846-852
54. Keating MT: Linkage analysis and long QT syndrome. Using genetics to study cardiovascular disease. Circulation 1992; 85: 1973-1986
55. Keating MT, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M: Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science 1991; 252: 704-706
56. Roy N, Kahlem P, Dausse E, Bennaceur M, Faure S, Weissenbach J, Komadja M, Denjoy I, Coumel P, Schwartz K, Guicheney P: Exclusion of Hras from long QT locus. Nature Genet 1994; 8: 113-114
57. Keating MT, Dunn C, Atkinson D, Timothy K, Vincent GM. Leppert M: Consistent linkage of the long-QT syndrome to the Harvey ras-1 locus on chromosome 11. Am J Hum Genet 1991; 49: 1335-1339
58. Benhorin J, Kalman YM, Medina A, Towbin JY, Rave-Harel N, Dye TD, et al: Evidence of genetic heterogeneity in the long QT syndrome. Science 1993; 260: 1960-1962
59. Curran M, Atkinson D, Timothy K, Vincent GM, Moss AJ, Leppert M, et al: Locus heterogeneity of autosomal dominant long QT syndrome. J Clin Invest 1993; 92: 799-803
60. Towbin JA, Li H, Taggart RT, Lehmann MH, Schwartz PJ, Satler CA, et al: Evidence of genetic heterogeneity in Romano-Ward long QT syndrome. Analysis of 23 families. Circulation 1994; 90: 2635-2644
61. Jiang C, Atkinson D, Towbin JA, Splawski I, Lehmann MH, Li H, et al: Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nature Genet 1994; 8: 141-147
62. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803
63. Warmke JW, Ganetzky B: A family of potassium channels related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994; 91: 3438-3442
64. Kr potassium channel. Cell 1995; 81: 299-307
65. Kass RS, Freeman LC: Potassium channels in the heart. Cellular, molecular and clinical implications. Trends Cardiovasc Med 1993; 3: 149-159
66. ATP channel. Nature 1994; 370: 456-469
67. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, et al: SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805-811
68. Bennett PB, Yazawa K, Makita N, George AL: Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995; 376: 683-685
69. Grace AA, Chien KR: Congenital long QT syndromes. Toward molecular dissection of arhythmia substrates. Circulation 1995; 92: 2786-2789
70. Marban E: Molecular approaches to arrhythmogenesis. In: Chien, KR, editor. Molecular Basis of Heart Disease. Philadelphia, W.B. Saunders Company, 1998
71. Bauer KA: Hypercoagulability-a new cofactor in the protein C anticoagulant pathway. N Engl J Med 1994; 330: 566-567
72. Majerus PW: Human genetics: bad blood by mutation. Nature 1994; 369: 14-15
73. Mann K, Rosenberg RD: Thrombosis. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: WB Saunders Co, 1998
74. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
75. Castellino FJ: Human protein C and activated protein C. Components of the human anticoagulation system. Trends Cardiovasc Med 1995; 5: 55-62
76. Dahlback B: Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614
77. Hajjar K: Factor V Leiden - an unselfish gene? N Engl J Med 1994; 331: 1585-1587
78. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
79. Zoller B, Dahlback B: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538
80. Greengard JS, Eichinger S, Griffin JH, Bauer KA: Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg ⇒ Gin mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-1562
81. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
82. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917
83. Lander ES, Schork NJ: Genetic dissection of complex traits. Science 1994; 265: 2037-2048
84. Pattengale PK, Steart TA, Leder A, Sinn E, Muller W, Tepler, I, et al: Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carying and expressing activated cellular oncogenes. Am J Pathol 1989; 135: 39-61
85. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P: Variation in the susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985; 57: 65 -73
86. Breslow JL: Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc Natl Acad Sci USA 1993; 90: 8314-8318
87. Keightley PD: Chewing the fat. Nature Genet 1995; 10: 125-126
88. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432
89. Rink TJ: Genetics. In search of a satiety factor. Nature 1994; 372: 406-407
90. Bennett WI: Beyond overeating. N Engl J Med 1995; 332: 673-674
91. Yamamoto T, Bishop RW, Brown MS, Goldstein JL, Russell DW: Deletion in cysteine-rich region of LDL receptor -impedes transport to cell surface in WHHL rabbits. Science 1986; 232: 1230-1237
92. Rapacz J, Hasler-Rapacz J, Taylor KM, Checovich WJ, Attie AD: Lipoprotein mutations in pigs are associated with elevated plasma cholesterol and atherosclerosis. Science 1986; 234: 1573-1577
93. Chien KR: Genes and physiology: Molecular physiology in genetically engineered animals. J Clin Invest 1996; 97: 901-909
94. Chien KR: Cannon Award Lecture: Cardiac muscle diseases in genetically engineered mice: the evolution of molecular physiology. Am J Physiol 1995; 269: H753-H766
95. Doevendans PA, Hunter JJ, Lembo G, Wollert KC, Chien KR: Strategies for studying cardiovascular diseases in transgenic and gene-targeted mice. In: Monastersky GM, Robl JM, editors. Strategies in transgenic animal science. Washington DC: American Society of Microbiology, 1995: 107-144
96. Field LJ: Transgenic mice in cardiovascular research. Annu Rev Physiol 1993; 55: 97-114
97. Lin MC, Rockman HA, Chien KR: Heart and lung disease in genetically engineered mice: the evolution of molecular physiology. Nature Med 1995; 1: 749-751
98. Jaenisch R: Transgenic animals. Science 1988; 240: 1468-1474
99. Bronson SK, Smithies O: Altering mice by homologous recombination using embryonic stem cells. J Biol Chem 1994; 269: 27155-27158
100. Tangirala RK, Casanada F, Miller E, Witzum JL, Steinberg D, Palinski W: Effect of the antioxidant N, N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1995; 15: 1625-1630
101. Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR, Evans RM: RXRα mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev 1994; 8: 1007-1018
102. Stoltzfus L, Rubin EM: Atherogenesis: insights from the study of transgenic and gene targeted mice. Trends Cardiovasc Med 1993; 3: 130-134
103. Paul M, Wagner J, Hoffmann S, Urata H, Ganten D: Transgenic rats: new experimental models for the study of candidate genes in hypertension research. Annu Rev Physiol 1994; 56: 811-829
104. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR: Ventricular expression of a MLC-2v-Ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995; 270: 23173-23178
105. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, et al: Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Nacl Acad Sci USA 1991; 88: 8277-8281
106. Rockman HA, Ono S, Ross RS, Jones LR, Karimi M, Bhargava V, et al: Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad Sci USA 1994; 91: 2694-2698
107. Dyson E, Sucov HM, Kubalak SW, Schmid-Schönbein G, Delano F, Evans RM, et al: Atrial-like phenotype is associated with embryonic ventricular failure in RXRα-/-mice. Proc Natl Acad Sci USA 1995; 92: 7386-7390
108. Kubalak SW, Doevedans PA, Rockman HA, Hunter JJ, Tanaka N, Ross J Jr, et al: Molecular analysis of cardiac muscle diseases via mouse genetics. In: Adolph KW, editor. Methods in Molecular Genetics. Orlando: Academic Press, 1996; 470-487
109. White D, Wall work J: Xenografting: probability, possibility, or pipe dream? Lancet 1993; 342: 879-880
110. Fan J, Wang J, Bensadoun A, Lauer SJ, Dang Q, Mahley RW, Taylor JM: Overexpression of hepatic lipase in transgenie rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci USA 1994; 91: 8724-8728
111. Paigen K: A miracle enough: the power of mice. Nature Medicine 1995; 1: 215-220
112. Lusis AJ: The mouse model for atherosclerosis. Trends Cardiovasc Med 1993; 3: 135-143
113. Tall A, Breslow J: Disorders of lipoprotein metabolism. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: WB Saunders Co, 1998
114. Tabas I, Krieger M: Disorders of cellular cholesterol metabolism. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: WB Saunders Co, 1998
115. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353
116. Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471
117. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-140
118. Reddick RL, Zhang SH, Maeda N: Atherosclerosis in mice lacking apo E: evaluation of lesional development and progression. Arterioscler Thromb 1994; 14: 141-147
119. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witzum JL: ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopies in lesions and high titers of auto antibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994; 14: 605-616
120. Steinberg D, Witzum J: The role of oxidized lipoproteins in atherogenesis. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: WB Saunders Co, 1998
121. Paszty C, Maeda N, Verstuyft J, Rubin EM: Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903
122. Van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, de Bruijn I, van Vlijmen B, van der Boom H, et al: Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993; 268: 10540-10545
123. Fazio S: Recent insights into the pathogenesis of type III hyperlipoproteinemia. Trends Cardiovasc Med 1993; 3: 191-196
124. Shimano H, Yamada N, Katsuki M, Shimada M, Gotoda T, Harada K, et al: Overexpression of apolipoprotein E in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against dietinduced hypercholesterolemia. Proc Natl Acad Sci USA 1992; 89: 1750-1754
125. Mulligan R: The basic science of gene therapy. Science 1993; 260: 926-932
126. Lever AML, Goodfellow PN. Gene therapy: Br Med Bull 1995; 51: l
127. Barr E, Leiden JM: Somatic gene therapy for cardiovascular disease. Recent advances. Trends Cardiovasc Med 1994; 4: 57-63
128. Nabel E: Gene therapy for cardiovascular disease. Circulation 1995; 91: 541-548
129. Miller AD: Human gene therapy comes of age. Nature 1992; 357: 455-460
130. Riessen R, Isner JM: Prospects for site-specific delivery of pharmacologie and molecular therapies. J Am Coll Cardiol 1994; 23: 1234-1244
131. Gerard RD, Meidell RS: Adenovirus-mediated gene transfer. Trends Cardiovasc Med 1993; 3: 171-177
132. Muzyczka N: Adeno-associated virus (AAV) vectors: will they work? J Clin Invest 1994; 94: 1351
133. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, et al: Single intrahiminal delivery of antisense cdc2 kinase and proliferating cell-nuclear antigen oligonucleotides result in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478
134. Lasic D, Papahadjopoulos D: Liposomes revisited. Science 1995; 267: 1275-1276
135. Leiden LM, Barr E: In Vivo gene transfer into the heart. In: Wolff JA, editor. Gene therapeutics: methods and applications of direct gene transfer. Boston: Birkhauser, 1994; 363
136. Simons M, Edelman ER, Dekeyser JL, Langer R, Rosenberg RD: Antisense c-myb oligonucleotides inhibit intimal smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70
137. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI: Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by C-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-828
138. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, et al: Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nature Genet 1994; 6: 335-341
139. Brown MS, Goldstein JL, Havel RJ, Steinberg D: Gene therapy for cholesterol. Nature Genet 1994; 7: 349-350
140. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, et al: Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992; 257: 1401-1403
141. Nabel EG, Yang Z-Y, Plautz G, Forough R, Zhan X, Haudenschild CC, et al: Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 1993; 362: 844-846
142. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J et al: Arterial gene therapy for therapeutic angiogenesis in patients with peripheral arterial disease. Circulation 1995; 91: 2687-2692
143. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763
144. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu L-Q, Bunting S, et al: Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662-670
145. Cantley L, Deuel T, Rosenberg RD: The molecular biology of restenosis. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: WB Saunders Co, 1998
146. Casscells W, Lappi DA, Baird A: Molecular atherectomy for restenosis. Trends Cardiovasc Med 1993; 3: 235-243
147. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ: Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989; 244: 1342-1344
148. Lemarchand P, Jones M, Yamada I, Crystal RG: In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993; 72: 1132-1138
149. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel, EG, et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-522
150. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-784
151. Wagner R: Gene inhibition using antisense oligodeoxynucleotides. Nature 1994; 372: 333-335
152. Davis AR: Current potential of antisense oligonucleotides as therapeutic drugs. Trends Cardiovasc Med 1994; 4: 51-55
153. Stein CA, Cheng Y-C: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993; 261: 1004-1012
154. Chien KR, Grace AA, Hunter JJ: Molecular basis of cardiac hypertrophy and heart failure. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: WB Saunders Co, 1998
155. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JN, Chien KR: Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. J Biol Chem, in press, 1997
156. Morgan HE, Baker KM: Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation 1991; 83: 13-25
157. Katz AM: Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart. Trends Cardiovasc Med 1995; 5: 37-44
158. Spudich J, Leinwand L: Contractile structure and function. In: Chien KR, editor. Molecular basis of heart disease. Philadelphia: WB Saunders Co, 1998
159. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M: Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 1993; 72: 463-469
160. Rosenzweig A, Seidman CE: Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem 1991; 60: 229-255
161. Hasegawa K, Fujiwara H, Doyama K, Miyama M, Fujiwara T, Suga S, et al: Ventricular expression of brain natriuretic peptide in hypertrophie cardiomyopathy. Circulation 1993; 88: 372-380
162. Hasegawa K, Fujiwara H, Doyama K, Mukoyama M, Nakao K, Fujiwara T, et al: Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyopathy. An immunohistocytochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies. Am J Pathol 1993; 142: 107-116
163. 1 mediated response. J Biol Chem 1990; 265: 13809-13817
164. Knowlton KU, Baracchini E, Ross RS, Harris AN, Henderson SA, Evans SM, et al: Co-regulation of the atrial natriuretic factor and cardiac myosin light chain-2 gene during α-adrenergic stimulation of neonatal rat ventricular cells. J Biol Chem 1991; 266: 7759-7768
165. 2+-ATPase gene. Circ Res 1992; 71: 9-17
166. Rockman HA, Knowlton KU, Ross J, Chien KR: In vivo murine cardiac hypertrophy. A novel model to identify genetic signaling mechanisms that activate an adaptive physiological response. Circulation 1993; 87: VII14-VII21
167. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, et al: Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990; 265: 20555-20562
168. Knowlton KU, Rockman HA, Itani M, Vovan A, Seidman CE, Chien KR: Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophie ventricular myocardium. J Clin Invest 1995; 96: 1311-1318
169. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, et al: Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy: Assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor dependent pathways. J Biol Chem 1996; 271: 9535-9545
170. Lee HR, Henderson SA, Reynolds R, Dunnmon P, Yuan D, Chien KR: Alpha-1 α-1 adrenergic stimulation of cardiac gene transcription in neonatal rat myocardial cells: Effects on myosin light chain-2 gene expression. J Biol Chem 1988; 263: 7352-7358
171. Meidell RS, Sen A, Henderson SA, Slahetka MF, Chien KR: Coordinate increases in myofibrillar protein synthesis during α-1 adrenergic stimulation of cultured rat myocardial cells. Am J Physiol 1986; 251: H1076-H1084
172. Parker TG, Schneider MD: Growth factors, protooncogenes, and plasticity of the cardiac phenotype. Annu Rev Physiol 1991; 53: 179-200
173. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993; 73: 413-423
174. Bogoyevitch MA, Glennon PE, Sugden PH: Endothelin-1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes. FEBS Lett 1993; 317: 271-275
175. Bogoyevitch MA, Glennon PE, Andersson MB, Clerk A, Lazou A, Marshall CJ, et al: Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes: the potential role of the cascade in the integration of 2 signaling pathways leading to myocyte hypertrophy. J Biol Chem 1994; 269: 1110-1119
176. Sadoshima J, Izumo S: Signal transduction pathways of angiotcnsin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 1993; 73: 424-438
177. Sadoshima J, Takahashi T, Jahn L, Izumo S: Roles of mechano-sensitive ion channels, cytoskeleton, and contractile activity in stretch-induced immediate-early gene expression and hypertrophy of cardiac myocytes. Proc Natl Acad Sci USA 1992; 89: 9905-9909
178. Komuro I, Yazaki Y: Intracellular signaling pathways in cardiac myocytes induced by mechanical stress. Trends Cardiovasc Med 1994; 4: 117-121
179. Long CS, Henrich CJ, Simpson PC: A growth factor for cardiac myocytes is produced by cardiac nonmyocytes. Cell Regul 1991; 2: 1081-1095
180. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh S-M, et al: Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 1995; 92: 1142-1146
181. Sheng Z, Pennica D, Wood WI, Chien KR: Cardiotrophin1 displays early expression in the murine heart tube and promotes cardiac myocyte suruival. Development 1996; 122: 419-428
182. Thorburn A, Thorburn J, Chen S-Y, Powers S, Shubeita HE, Feramisco JR, et al: HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem 1993; 268: 2244-2249
183. 2-adrenergic receptor. Science 1994; 264: 582 -586
184. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van Bilsen M, O'Brien TX, et al: Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993; 55: 77-95
185. Little WC, Downes TR: Clinical evaluation of left ventricular diastolic performance. Prog Cardiovasc Dis 1990; 32: 273-290
186. Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homey CJ, et al: Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest 1993; 91: 907-914
187. Muntz KH, Zhao M, Miller JC: Downregulation of myocardial β-adrenergic receptors. Receptor subtypes selectivity. Circ Res 1994; 74: 369-375
188. Lembo G, Rockman HA, Hunter JJ, Warburton C, Koch WJ, Ma L, et al: Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency. J Clin Invest 1996; 98: 2648-2655
189. Hunter JJ, Zhu H, Lee KJ, Kubalak SW, Chien KR: Targeting gene expression to specific cardiovascular cell types in transgeic mice. Hypertension 1993; 22: 608-617
190. Sauer B, Henderson N: Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage PI. Proc Natl Acad Sci USA 1988; 85: 5166-5170
191. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K: Deletion of DNA polymerase β gene segment in T cells using cell type-specific gene targeting. Science 1994; 265: 103-106
192. Lembo G, Hunter JJ, Chien KR: Signaling pathways for cardiac growth and hypertrophy. Recent advances and prospects for growth factor therapy. In: Claycomb WC, Di Nardo P, editors. Annals NY Academy Science: Cardiac growth and regeneration. New York: New Academy of Sciences, 1995; 752: 115-127
193. Schneider MD, Parker TG: Cardiac growth factors. Prog Growth. Factor Res 1991; 3: 1-26
194. Fishman MC, Stainier DYR: Cardiovascular development. Prospects for a genetic approach. Circ Res 1994; 74: 757-763
195. Chien KR: Molecular analysis of cardiac developmental phenotypes: Problems, progress and prospects. In: Clark EB, Markwald RR, Takao A, editors. Developmental mechanisms of heart disease. New York: Futura Press, 1995; 3-27
196. Zhou MD, Sucov HM, Evans RM, Chien KR: Retinoid dependent pathways suppress myocardial cell hypertrophy. Proc Natl Acad Sci USA 1995; 92: 7391-7395
197. Chambon P: The retinoid signaling pathway: molecular and genetic analyses. Sem Cell Biol 1994; 5: 115-125
198. Neer EJ, Clapham DE: Signal transduction through G proteins in the cardiac myocyte. Trends Cardiovasc Med 1992; 2: 6-11
199. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg H-P, McKenna WJ, Seidman CE, et al: A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62: 999-1006
200. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, et al: Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995; 332: 1058-1064
201. Thierfelder L, Watkins H, MacRae CA, Lamas R, McKenna WJ, Vosberg H-P, et al: α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994; 77: 701-712
202. McKenna WJ, Watkins H: Hypertrophic cardiomyopathy. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw Hill, 1995; 4253-4272
203. Schwartz K, Carrier L, Guicheney P, Komajda M: Molecular basis of familial cardiomyopathies. Circulation 1995; 91: 532-540
204. Sweeney HL, Straceski AJ, Leinwand LA, Tikunov BA, Faust L: Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem 1994; 269: 1603-1605
205. Weatherall D: Science and the quiet art: The role of medical research in health care. New York: WW Norton, 1995
206. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Perriard J-C, Chen KR, Caroni P: MLP-deficient mice exhibit a disruption of cardiac myofibrillar organization, dilated cardiomyopathy, and heart failure. Cell 1997, in press